Join Growin Stock Community!

Taysha gene therapies, inc.TSHA.US Overview

US StockHealthcare
(No presentation for TSHA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TSHA AI Insights

TSHA Overall Performance

TSHA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TSHA Recent Performance

0.55%

Taysha gene therapies, inc.

0.05%

Avg of Sector

-0.31%

S&P500

TSHA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TSHA Key Information

TSHA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TSHA Profile

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Price of TSHA

TSHA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TSHA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.36
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
196.65
PB Ratio
5.68
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1583.66%
Revenue Growth (YoY)
-36.36%
Profit Growth (YoY)
-36.36%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.36
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
196.65
PB Ratio
5.68
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1583.66%
Revenue Growth (YoY)
-36.36%
Profit Growth (YoY)
-36.36%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is TSHA's latest earnings report released?

    The most recent financial report for Taysha gene therapies, inc. (TSHA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TSHA's short-term business performance and financial health. For the latest updates on TSHA's earnings releases, visit this page regularly.

  • How is TSHA's revenue growth?

    In the latest financial report, Taysha gene therapies, inc. (TSHA) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does TSHA have?

    At the end of the period, Taysha gene therapies, inc. (TSHA) held Total Cash and Cash Equivalents of 299.94M, accounting for 0.95 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TSHA's EPS continuing to grow?

    According to the past four quarterly reports, Taysha gene therapies, inc. (TSHA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.09. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TSHA?

    Taysha gene therapies, inc. (TSHA)'s Free Cash Flow (FCF) for the period is -24.27M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 12.12% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of TSHA?

    The latest valuation data shows Taysha gene therapies, inc. (TSHA) has a Price-To-Earnings (PE) ratio of -11.71 and a Price/Earnings-To-Growth (PEG) ratio of 39.8. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.